Veterinary cardiologist, Dr. Hayley McDonald Explains All about Felicyn CA-1
Felycin®-CA1 (sirolimus delayed-release tablets) is the first disease-modifying drug that can give hope to owners of cats with subclinical hypertrophic cardiomyopathy (HCM).Felycin®-CA1 is the first and only FDA conditionally approved once-weekly drug for the management of ventricular hypertrophy in cats with subclinical HCM.
Left Atrial Function as an Early Indicator of Thromboembolic Risk in Cats with HCM
Hypertrophic cardiomyopathy (HCM) remains the most common heart disease diagnosed in cats, and one of its most serious complications is the development of thromboembolism. Identifying early warning signs of clot formation is a critical step in improving outcomes for feline patients.